Gossamer Bio(GOSS.US)

Last Updated 19:00:00 ET
longbridge loading
Company Encyclopedia
View More
name
Gossamer Bio
GOSS.US
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds.
1.813 T
GOSS.USMarket value -Rank by Market Cap -/-

Financial Score

19/05/2026 Update
D
BiotechnologyIndustry
Industry Ranking281/387
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE215.10%A
    • Profit Margin-324.82%E
    • Gross Margin100.00%A
  • Growth ScoreE
    • Revenue YoY-55.42%E
    • Net Profit YoY-252.07%E
    • Total Assets YoY-54.06%E
    • Net Assets YoY-2483.73%E
  • Cash ScoreD
    • Cash Flow Margin94.38%C
    • OCF YoY-55.42%E
  • Operating ScoreD
    • Turnover0.27D
  • Debt ScoreE
    • Gearing Ratio225.28%E

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    U.S. stock night trading volatility: Gossamer Bio rose 5.19% in after-hours trading, boosted by dual positive factors of debt restructuring and successful trials enhancing market confidence

    Price Alert·
    US
    GOSS
    -43.32%
    Price Alert·
    US
    GOSS
    -43.32%

    GOSS 2-WEEK DEADLINE ALERT: Gossamer Bio Investors With Losses May Seek to Lead the Class Action After Executives Allegedly Concealed Placebo Risk: HBSS

    PR Newswire·
    US
    GOSS
    -43.32%
    US
    BBH
    -1.03%
    US
    XBI
    -2.31%
    PR Newswire·
    US
    GOSS
    -43.32%
    US
    BBH
    -1.03%
    US
    XBI
    -2.31%

    Gossamer Bio Reports Q1 2026 Results: Full Earnings Call Transcript

    benzinga_article·
    US
    GOSS
    -43.32%
    US
    XBI
    -2.31%
    US
    SBIO
    -3.43%
    benzinga_article·
    US
    GOSS
    -43.32%
    US
    XBI
    -2.31%
    US
    SBIO
    -3.43%

    Here are the major earnings after the close Monday

    MSN·
    US
    GOSS
    -43.32%
    US
    AGYS
    +4.25%
    US
    MUFG
    +1.86%
    MSN·
    US
    GOSS
    -43.32%
    US
    AGYS
    +4.25%
    US
    MUFG
    +1.86%

    12 Health Care Stocks Moving In Monday's Pre-Market Session

    benzinga_article·
    US
    GOSS
    -43.32%
    US
    LTRN
    -4.46%
    US
    AIM
    +61.26%
    benzinga_article·
    US
    GOSS
    -43.32%
    US
    LTRN
    -4.46%
    US
    AIM
    +61.26%
    © 2026 Longbridge｜Disclaimer